Clinical Trials on Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
Total 417 results
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 MutationFrance, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
-
3H (Suzhou) Pharmaceuticals Co., Ltd.Not yet recruitingSolid Tumors With FGFR2 Alterations, AdultUnited States
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France
-
Deciphera Pharmaceuticals LLCTerminatedMetastatic Solid Tumors | Locally Advanced Tumors | Cancers With MET Genomic Alterations | Cancers With TRK Genomic AlterationsUnited States
-
National Cancer Center, JapanEisai Co., Ltd.Active, not recruitingAdvanced or Recurrent Solid Tumors | FGFR Gene AlterationsJapan
-
Incyte CorporationTerminatedAdvanced or Metastatic Solid Tumors | FGFR Mutations | FGFR TranslocationsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPatients With Advanced or Metastatic Solid TumorsFrance
-
Disphar International B.V.CompletedPatients With Advanced or Metastatic Solid Tumors
-
BeiGeneCompletedFor Participants With Advanced Solid Tumors Failed With Previous Lines of TreatmentAustralia
-
Taiho Oncology, Inc.TerminatedAdvanced Solid Tumors With HER2 Abnormalities | Advanced Solid Tumors With HER3 AbnormalitiesUnited States, Spain, France, United Kingdom
-
Jiangsu Simcere Pharmaceutical Co., Ltd.RecruitingAdvanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene FusionChina
-
Novartis PharmaceuticalsCompletedEstrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA GeneUnited States, Netherlands, Spain, Germany, United Kingdom
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Nektar TherapeuticsCompletedAdvanced or Metastatic Solid Tumors in Patients With Hepatic ImpairmentUnited States
-
Tyra Biosciences, IncRecruitingSolid Tumor | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | FGFR3 Gene Mutation | Urinary Tract Cancer | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Non-muscle-invasive Bladder Cancer | FGFR3 Gene Alteration | Urinary... and other conditionsAustralia, United States, France, Spain
-
Peking UniversityRecruitingConditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid TumorChina
-
Turning Point Therapeutics, Inc.Active, not recruitingAdvanced Solid Tumor | Metastatic Solid Tumors | MET Gene AlterationsUnited States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
YM BioSciencesCIMYM BioSciencesCompleted
-
Aadi Bioscience, Inc.RecruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmKorea, Republic of, United States, Puerto Rico
-
AmgenCompletedPart 1- Advanced Solid Tumors | Part 2- Advanced or Metastatic Gastric Cancer | Part 2- Advanced or Metastatic GEJJapan
-
Frontier Medicines CorporationRecruitingColorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C MutationsUnited States
-
Semafore PharmaceuticalsSignalRX Pharmaceuticals, Inc.CompletedCancer | Advanced or Metastatic Solid Tumors | Solid CancersUnited States
-
Nanostim, Inc.UnknownAtrial Fibrillation With 2 or 3° AV or Bifascicular Bundle Branch (BBB) Block | Normal Sinus Rhythm With 2 or 3° AV or BBB Block | Sinus Bradycardia With Infrequent Pauses or Unexplained Syncope With EP FindingsGermany, Netherlands, Czech Republic
-
Taiho Oncology, Inc.TerminatedNon-Small Cell Lung Cancer | KRAS Gene Mutation | Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsUnited States
-
Merck Sharp & Dohme LLCRecruitingAdvanced or Metastatic Solid TumorsCanada, Switzerland, United States
-
Merck Sharp & Dohme LLCActive, not recruitingAdvanced or Metastatic Solid TumorsChile, Hungary, Korea, Republic of, South Africa, Spain, Japan
-
Merck Sharp & Dohme LLCRecruitingAdvanced or Metastatic Solid TumorsUnited States, Canada, Israel, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium
-
BayerRecruitingLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionUnited States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedLocally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionChina
-
Memorial Sloan Kettering Cancer CenterChugai Pharma USARecruitingPrimary Extra-cranial Solid Tumor | Recurrent or Refractory Glypican 3 (GPC3)United States
-
Fusion Pharmaceuticals Inc.TerminatedBreast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Liver Cancer | Bladder Carcinoma | Susceptible FGFR3 Genetic Alterations | FGFR3 | FGFR3 Overexpression | FGFR3 Receptor | FGFR3 Protein OverexpressionUnited States, Australia
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownMSI-H or dMMR Advanced Solid TumorsChina
-
University of California, IrvineWithdrawnAnesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries | Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)United States
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic Solid TumorsUnited States, France
-
Tyra Biosciences, IncRecruitingSolid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced CholangiocarcinomaUnited States
-
PlexxikonTerminatedSolid Tumor | Tenosynovial Giant Cell Tumor | Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion MutationsUnited States
-
TakedaCompletedCarcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid TumorsSpain, Italy, Netherlands, France
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic Urinary Tumors | Other Solid TumorsChina
-
Ascentage Pharma Group Inc.CompletedPatients With Advanced Solid Tumor or LymphomaUnited States
-
Novartis PharmaceuticalsCompletedCancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological MalignanciesUnited States
-
PfizerTerminatedAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsUnited States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
-
China Medical University HospitalUnknownCondition 1. Children With ALL Are Still Alive and the Age of 18 Years of Age. | Condition 2. Has Been Completed to Guide the Treatment Regimen Were in Remission. | Condition 3. Caregiver Can or Taiwanese Language Communicator.Taiwan
-
Fudan UniversityNot yet recruitingthe Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced MelanomaChina
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingBreast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid TumorsChina
-
Crescendo Biologics Ltd.RecruitingAdvanced and/or Metastatic Solid TumoursSpain, United Kingdom, Netherlands, United States
-
Crescendo Biologics Ltd.University Medical Center GroningenActive, not recruitingAdvanced and/or Metastatic Solid TumoursNetherlands
-
Novartis PharmaceuticalsCompletedAdvanced or Recurrent Solid TumorsJapan